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Introduction
A recent review has discussed the
economic value of vaccine for developed
countries. The situation is quite different
in developing countries, and we examine
the situation in Brazil. Vaccines are of
fundamental importance for the control of
infectious diseases, especially among the
population that lives in poor sanitary
conditions. Also, vaccines can generate
herd effects that result in protection even
among those who have not been vaccinat-
ed, which can be of particular value to
poor individuals who are not reached by
health services. In appreciation of this
importance, various international agen-
cies, including the Pan American Health
Organization (PAHO) and UNICEF, un-
dertake large-scale procurement of vac-
cines for supply to developing countries.
This scale of procurement has allowed
these agencies to obtain very low prices. In
Brazil, the Constitution includes the right
to health care, which has led the govern-
ment to formulate a goal of universal
vaccination free of charge, a cost-effective
measure against many important infec-
tious diseases. Universal vaccination is a
fundamental role of the federal, state, and
municipal governments through the cur-
rent unified public health care system
(Sistema U ´nico de Sa ´ude [SUS]).
To achieve this goal, in 1985 the
Ministry of Health (MH) launched a
national immunization program and a
plan to achieve self-sufficiency in vaccine
production through local institutions. The
latter program included support for inno-
vation and technological development.
The success of this platform has allowed
the MH to purchase vaccines from
domestic public vaccine production insti-
tutes at prices comparable to those ob-
tained by PAHO and UNICEF. Most of
the research institutes in less developed
countries (LDCs) are the descendants of
the various Pasteur-like institutes founded
in the early 1900s. Throughout their lives,
these institutions maintained scientific
research programs but had limited capa-
bility for meeting good manufacturing
practices (GMPs) in vaccine production.
The implementation of the MH policy of
local procurement required substantial
investments to upgrade the production
capabilities of these institutes.
The largest volume vaccine producer in
Brazil is the Butantan Institute in Sa ˜o
Paulo. The Institute, part of the Sa ˜o Paulo
State Office of Health, was founded in
1901 to help in the control of bubonic
fever and later became a producer of
antivenoms and antitoxins. It maintains a
scientific research program funded by
grants from federal and state agencies.
The administration of vaccine production
is carried out by the Butantan Foundation,
which is a separate, private, non-profit
organization closely affiliated with the
Institute (The Board of Directors of
Butantan Institute and the Board of
Curators of Butantan Foundation are
composed of the same persons). Because
of its legal structure, the Foundation is free
of the usual administrative constraints of
government agencies. In 2010, around 53
million doses of vaccine were used in the
vaccination program implemented by the
MH (Table 1). This comprises approxi-
mately 100 million doses of antigens, and
of these, Butantan provided about 80%.
The MH distributes vaccines free of
charge to the whole country through
about 25,000 health care centers, fulfilling
a fundamental role of the SUS.
The situation in Brazil contrasts with
that of other developing countries. In
India, private for-profit companies have
emerged as the major vaccine producers.
In China, the situation is mixed, with a
number of government controlled non-
profit vaccine production institutes and
several emerging private sector producers.
The private Indian manufacturers have, in
several cases, become major vaccine
exporters and sell large quantities to
UNICEF. The Chinese manufacturers
have largely remained as suppliers for
local needs. In both India and China,
major developed country for-profit vac-
cine manufacturers are buying interests in
the local companies. There are no private
sector for-profit vaccine manufacturers in
Brazil.
Vaccine Development
The Butantan Institute has employed
four methods to obtain new vaccine
technology.
1. Technology transfer from for-profit
vaccine producers in developed coun-
tries
2. Technology transfer from public sector
institutions in developed countries
3. Independent development
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Technology Transfer from For-
Profit Companies
While this approach can be successful, it
has certain disadvantages. The companies
are understandably reluctant to create
competitors with knowledge and capabil-
ities in the most up-to-date production
methods and most advanced vaccines.
Thus, the developing country partner
may obtain out-of-date technology for
older vaccines. Furthermore, the technol-
ogy transfer agreements may not result in
autonomous production capability, as they
may require that the recipient of the
technology obtains certain essential mate-
rials from the developed country supplier.
The agreement may also impose a mini-
mum price at which the vaccine can be
sold, preventing the achievement of the
most cost-effective programs. The agree-
ment may not provide for the recipient
partner to obtain new developments in
production technology, imperiling sus-
tained economic feasibility. If the agree-
ment calls for stepwise technology transfer
beginning with filling and labeling, there
may be no guarantee of moving to the
next step, resulting in a requirement to
continue importing in bulk. The technol-
ogy supplier may also demand quantities
of vaccine for clinical trials without clear
benefit for the developing country recipi-
ent or the country itself. Despite all the
problems mentioned above, this model of
technological transfer allowed a successful
association between Butantan Institute
and Sanofi-Pasteur for the production of
seasonal influenza vaccine. The process
started in 1999–2000 and the production
of the first vaccine lots occurred in 2011.
In the beginning, the vaccine was obtained
ready for use and Butantan had to
perform the quality control. This stage
was followed by the implementation of the
formulation and filling technologies, which
allowed the purchase of the vaccine in
bulk. In parallel, human resources were
trained in all steps of the production chain
and funds were obtained from federal and
state agencies for the construction of a
production plant. In 2008, the start up of
the plant occurred. This important
achievement is not only strategic for












Intradermal BCG vaccine At birth 3,121,271 3,121,271 Fundac ¸a ˜o Ataulpho Paiva, RJ, Brazil





2, 4, and 6 months 8,550,731 34,202,924 25,652,193 DTwP – Instituto Butantan, SP, Brazil
Hib– GSK (technology transfer agreement with
Bio-Manguinhos, RJ, Brazil)
OPV (oral polio vaccine) 2, 4, 6, and 15 months 41,771,039














3, 5, and 15 months 4,104,357 - - Novartis (technology transfer agreement with
Fundac ¸a ˜o Ezequiel Dias, MG, Brazil)
Yellow fever vaccine 9 months and booster
every 10 years
6,699,459 6,699,459 - Bio-manguinhos/Fiocruz, RJ, Brazil
MMR (measles, mumps, and
rubella vaccine)




15 months and 4 years 5,456,881 16,370,643 16,370,643 Instituto Butantan, SP, Brazil
DT (diphtheria and tetanus
vaccine)
Booster every 10 years 14,760,432 29,520,864 29,520,864 Instituto Butantan, SP, Brazil
Seasonal influenza vaccine Once a year for those
above 60 years of age
16,223,394 - Sanofi-Pasteur (technology transfer agreement
with Instituto Butantan)
Influenza H1N1 vaccine Campaign in 2010 3,140,513 - Sanofi-Pasteur (technology transfer agreement
with Instituto Butantan), GSK, and Novartis
Pneumococcal 23-valent
polysaccharide vaccine
Once for those above
60 years of age
249,773 - Sanofi-Pasteur
Total 53,233,774 104,560,161 86,188,700
aSource: Datasus (http://tabnet.datasus.gov.br/cgi/tabcgi.exe?pni/cnv/DPniuf.def), Ministry of Health (http://portal.saude.gov.br/portal/saude/profissional/area.
cfm?id_area=1448), and Fiocruz (http://www.fiocruz.br/bio_eng/cgi/cgilua.exe/sys/start.htm?sid=208) and (http://www.fiocruz.br/bio_eng/cgi/cgilua.exe/sys/start.
htm?infoid=549&sid=227).
bConsidering the vaccines produced in Brazil (only those presenting all the steps in the production chain, such as BCG, Hepatitis B, DTwP+Hib, DTwP, DT and yellow
fever), a total of 53,233,774 doses of vaccine were produced and given in Brazil. This represents 104,560,161 doses of antigens produced and given in Brazil. Butantan
Institute produced 86.188.700 doses of these antigens (D, T, wP and hepatitis B).
cIncludes vaccination campaigns and
dvaccines included in 2010 in the vaccination schedule.
doi:10.1371/journal.pntd.0001300.t001
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the case of a pandemic influenza [1].
Technology Transfer from
Public Sector Institutions
As Butantan has proven itself to be
technically competent with qualified per-
sonnel and modern facilities, it has sought
new vaccine candidates from public health
research institutes and universities in
developed countries. In these programs,
Butantan works in partnership to move
from pilot-scale production to confirma-
tion of proof of principle, to preparation of
lots for clinical testing, and finally to large-
scale production. Butantan is executing
two such programs in collaboration with
the United States National Institutes of
Health for a pentavalent rotavirus vaccine
and a tetravalent dengue vaccine. It is also
undertaking programs with Children’s
Hospital Boston, of the Harvard Medical
School, for a killed unencapsulated whole
cell pneumococcal vaccine and with the
Sabin Vaccine Institute and George
Washington University for the Necator
and Schistosoma parasite worms vaccines.
Butantan is also working with the Infec-
tious Diseases Research Institute in Seattle
and the University of Washington on a
Leishmania vaccine for dogs, which are the
main reservoir for this disease in Latin
America. The main advantage of this kind
of partnership is that both sides will
complement efforts to bring the potential
vaccines to the market at a reduced time
when compared with a development made
by each partner alone. Depending on the
case, the proof of principle in animal
models was previously defined. Therefore,
in these cases, the scale up of the bench
process and the production under GMP
conditions for the pre-clinical and Phase
I/II clinical tests are the major challenges
faced by the partners. It is important to
point out that this kind of association is
only feasible if the recipient institution
counts with well trained human resources
and is an active and qualified manufac-
turer with a well established market. From
the point of view of the university and
public research institutes involved, this
represents a chance of high profit return
and project success.
Independent Development
Since 1984, the Butantan Institute has
produced diptheria, tetanus, and whole
cell pertussis (DTwP) trivalent vaccine for
the full cohort of children born each year
in Brazil, which currently totals 3.2 million
infants. This DTwP vaccine has been
highly efficacious, lowering the incidence
of all three diseases substantially between
1990 and 2008 (Figure 1). In contrast to
the serious adverse reactions observed
elsewhere, such events were not reported
for the whole cell pertussis vaccine (wP)
produced by Butantan. In Japan, the
problem of adverse reactions has been
solved by using isolated proteins in an
acellular vaccine that has a production
cost 50-fold higher than the whole cell
vaccine [2]. The World Health Organiza-
tion (WHO) and PATH have stated that
there is no sound rationale for LDCs to
replace whole cell vaccine with acellular
vaccine. In Brazil, such replacement
would increase the cost of vaccination
against pertussis by about $100 million per
year. To solve this problem, Butantan
developed a process to remove lipopoly-
saccharide (LPS) from the bacterium to
reduce inflammatory and febrile reactions.
This new vaccine (wPlow), formulated as
DTwPlow, can be supplied at the same
price as the regular whole cell DTwP
vaccine. This vaccine was subjected to the
standard potency test of intra-cerebral
challenge in mice and was shown to
induce levels of protection similar to
classical DTwP (W. Dias, A. van der
Ark, M. Sakauchi, F. Kubrusly, A. Prestes
et al., unpublished data). Furthermore,
clinical evaluations were performed in
infants and showed immunogenicity sim-
ilar to classical DTwP and no significant
side effects [3]. Production optimization of
DTwPlow may increase the yield to about
200 million doses per year, allowing
Butantan to export some quantities.
Moreover, the LPS removed in this
process can be hydrolyzed to monophos-
poryl lipid A (MPLA), a non-toxic product
that can be used as an adjuvant for
vaccines like those against influenza
H5N1 and pandemic H1N1. The use of
MPLA would allow a 4-fold reduction in
antigen per dose, simultaneously increas-
ing production capacity and lowering per-
dose cost [4,5]. As a byproduct of the
production process of the wPlow vaccine,
Butantan can produce kilograms of MPLA
with only 10 micrograms needed per dose
of influenza vaccine. Butantan has agreed
to supply another Brazilian public sector
vaccine producer, Fiocruz-Biomanguin-
hos, with DTwPlow ready for combination
with lyophilized Haemophilus influenzae type
b (Hib) vaccine. To date, Hib has been
resuspended with DTwP by the staff at the
health care centers to make the tetravalent
vaccine right before use.
Since 1996, Butantan has produced
recombinant hepatitis B vaccine, and 150
million doses have been administered to
children and newborns. A tetravalent
vaccine of DTwPlow and hepatitis B is
under clinical trial and could be further
formulated as a pentavalent vaccine by the
addition of Hib produced by Fiocruz-
Biomanguinhos. Regarding the Hib vac-
cine, its production by Fiocruz-Bioman-
guinhos is under a technology transfer
agreement with GlaxoSmithKline that
limits the export of the vaccine only to
Mercosur countries (full members: Argen-
tina, Brazil, Paraguay, and Uruguay;
associate members: Bolivia, Chile, Colom-
bia, Equador, Peru, and Venezuela). To
overcome this limitation, Butantan is
independently developing a Hib vaccine.
This vaccine is expected to have a lower
cost of production because of an innova-
tive conjugation method for the polysac-
charide antigen and the carrier protein
resulting in higher yield. In addition, the
carrier protein is also regularly produced
by Butantan, avoiding its acquisition in
bulk and resulting in a decrease of the final
price. Thus, a pentavalent vaccine formu-
lated with the Butantan Hib vaccine could
perhaps be provided to LDCs at a price
comparable to that obtained by PAHO
and UNICEF. Butantan is particularly
interested in multivalent vaccines because
they have many advantages, such as
inoculation of a single dose of adjuvant
and the use of a single disposable syringe
for many vaccines. In Brazil, the cost of
vaccine administration is borne by munic-
ipalities and is not included by the MH in
the cost of immunization. Between 2 and
18 months of age, each Brazilian receives
seven injections to receive DTP, hepatitis
B, and Hib vaccines (Table 1). Each dose
contains aluminum hydroxide adjuvant,
which, although used safely since 1926, is
considered painful.
Butantan is also developing new pneu-
mococcal vaccines that should be less
expensive than existing ones. Pneumococ-
cal-conjugated vaccines containing poly-
saccharide from seven, ten, or 13 serotypes
have prices that are prohibitive for most
LDCs. Also, these vaccines may induce
serotype replacement, requiring develop-
ment of new formulations containing
additional serotypes [6–8]. Butantan is
taking two approaches to develop pneu-
mococcal vaccines. The most promising
candidate was mentioned in the previous
section and is a partnership with Chil-
dren’s Hospital Boston involving a Strepto-
coccus pneumoniae strain without capsule as a
simple whole cell inactivated bacterial
vaccine. The second candidate employs
the pneumococcal surface protein A
(PspA). The combination of PspA with
DTwPlow has been shown to improve
www.plosntds.org 3 November 2011 | Volume 5 | Issue 11 | e1300protection against challenge with several
pneumococcal strains in mice [9]. Fur-
thermore, PspA may be conjugated with
polysaccharides, reducing the need for a
large number of polysaccharide serotypes
in the vaccine.
A vaccine combining DTwPlow, hepati-
tis B, Hib, and pneumococcal antigens
could substantially reduce the cost to
provide protection against a wide range
of infections and with fewer injections. A
further improvement would be the addi-
tion of the Salk inactivated polio vaccine.
However, the development of such com-
plex vaccines would require extensive
clinical trials.
In Brazil, partial protection against
tuberculosis is achieved by intradermal
delivery of bacille Calmette-Gueri (BCG)
at birth (Table 1). In addition, a first dose
of hepatitis B vaccine at birth is being
introduced to reduce mother-to-child
transmission. A clinical trial has demon-
strated the effectiveness and reduced pain
of injection of a combined hepatitis B–
BCG vaccine without aluminum hydrox-
ide adjuvant in the first dose at birth,
without changing the following second
and third doses of hepatitis B vaccination
(Table 1) [10].
The scheme in Figure 2 summarizes the
planned development of new and com-
bined vaccines at Butantan. These vac-
cines could provide substantial benefits for
the national immunization program and
thus for public health.
Partnership with For-Profit
Vaccine Producers in Less
Developed Countries
With well trained personnel and a
regular and qualified manufacturer, these
features allowed Butantan to achieve the
independent developments illustrated
above. These are features also presented
by other manufacturers in LDCs that may
combine their efforts to develop new
vaccines. In this case, for a successful
partnership, a very clear agreement defin-
ing the fee, royalties, markets, and shares
should be determined. Butantan is discuss-
ing this kind of partnership with members
of the DCVMN (Developing Countries
Vaccine Manufacturers Network) since
DTwPlow can be a base for multiple
vaccines (Figure 2) for LDCs. Such practice
should be encouraged for all the members
of the DCVMN for the benefit of all.
Final Remarks
The national immunization program
launched in 1985 in Brazil has provided
immensepublichealthbenefitstothe whole
country free of charge to individuals. These
benefits were achieved through sustained
long-term efforts to develop all elements of
the program, including product develop-
ment, production, delivery, and disease
surveillance. Vaccination of children,
adults over 60 years, and persons with
underlying health conditions that make
them more susceptible to acquiring pre-
ventable infections with the existing vac-
cines provided by the MH and health care
personnel are all covered free of charge
through the SUS (Table 1). This is assured
by the Brazilian Constitution and has
created a large national market allowing
sustainable vaccine production in contrast
to the export-oriented market practiced by
many private vaccine producers. Although
this market is guaranteed by the govern-
ment, there are several hurdles faced by
Butantan. The production has to be done
in advance, even when Butantan does not
know the amount of vaccines to be
purchased, which may vary from year to
year. In addition, the payment depends on
budget approval, which may also vary from
months up to years. However, this experi-
ence, focusing on creation of domestic
capabilities in the public sector to attend
this demand, is positive and may present an
interesting model for other LDCs not only
Figure 1. Coverage of DTP vaccination and incidence per 100,000 inhabitants of diphtheria, tetanus (except neonatal), and
pertussis in Brazil from 1990 to 2008. Source: [12].
doi:10.1371/journal.pntd.0001300.g001
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also to develop sustainable technological
institutions in vaccine development and
production. Public vaccination resulted in
the political decision of the MH to promote
self-sufficiency in immunobiologicals, pro-
viding efficacious vaccines at an affordable
cost and prioritizing vaccine production by
a few public health Pasteur-like institutes
that received support to renovate their
production facilities and to introduce
GMPs. This decision also led to other
actions and necessities. To guarantee the
quality of the vaccines, it created the
independentNational ImmunologicalCon-
trol Laboratory (INCQS), which tests each
lot of the vaccines delivered to the MH
central storage facility (both located in Rio
de Janeiro). If the lot does not conform with
composition, potency, and safety require-
ments, it is destroyed and the producer is
not refunded for its cost, incurring a hard
penalty for non-compliance. This same
analysis and certification are also applied
for imported vaccines. Besides this, a
federal regulatory agency (ANVISA) was
created that certifies the production labo-
ratories and promotes a move to full
compliance with WHO GMP guidance, a
process that is not instantaneous but
dependson investmentsthat the MHbegan
to make available starting in 1985. All new
plants, like Butantan’s influenza plant, were
built under these new regulations. Older
plants are in a stepwise process of reform
and if funds areavailable, total replacement
will be considered. Funds for reform,
replacement, or construction of a new plant
are not an automatic process for Butantan,
which belongs to the State of Sao Paulo. At
this moment, Butantan is pursuing WHO
prequalificationinordertohave permission
to provide the vaccines to PAHO and
UNICEF. Most of the production plants
were built in the 1980s under past regula-
tions and do not present the features
necessary for current legislative approval.
Therefore, modifications on the plants to
conform to the new regulations are under
way. It is important for a public producer
that itsvaccinesberecognized asefficacious
and safe as any other vaccine produced and
prequalified by WHO in order to have
public confidence and to become an
important vaccine provider to other coun-
tries. Nevertheless, the vaccines that have
been produced by Butantan since 1985
were approved by INCQS, the production
plants were approved by ANVISA, and the
massive immunization of 80 million chil-
dren with about 350 million antigen doses
in 26 years, as well as the immunization of
20 million adults over 60 years of age, was
shown to be safe and efficacious, decreasing
significantly the number of diseases
(Figure 1). In order to continue with its
mission to provide immunobiologicals for
public health problems, Butantan needs to
innovate constantly.
While collaboration between public sec-
tor institutions and private sector pharma-
ceutical companies (from both developed
countries and LDCs) can also be successful
and complementary for obtaining know-
how for vaccine production, it is essential
that the resulting products are affordable to
ensure cost-effective programs. In addition,
anyadopted strategymust consider keeping
high confidence in vaccines, which is
usuallygreateramongpopulationsinLDCs
than in industrialized countries [11]. Public
Figure 2. Schematic representation of combined vaccines as well as new vaccines under development at Instituto Butantan with
the potential to impact public health.
doi:10.1371/journal.pntd.0001300.g002
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ery of immunization services and facilitate
the introduction of new vaccines as they
become available. Finally, the country
should ensure the capability to undertake
rigorous epidemiological studies to guide
and evaluate the delivery of vaccination
services.
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